Affymax Cash and ST Investments: 115.25M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
None selected
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
AFFY Cash and ST Investments Rankings
| Overall | 58th percentile | 1876 of 4527 |
| Sector | 68th percentile | 161 of 519 in Healthcare |
| Industry | 71st percentile | 47 of 163 in Biotechnology |
AFFY Cash and ST Investments Range, Past 5 Years
| Minimum | 225.34M | Dec 2006 |
| Maximum | 225.34M | Dec 2006 |
| Average | 225.34M |
About Cash and Short Term Investments
Cash and Short Term investments is the sum of two balance sheet line items: cash and equivalents and short term investments in marketable securities
Learn More
You may also be interested in these AFFY related companies
AFFY News
$AFFY CEO will present at the 14th Annual BIO CEO & Investor Conference on Tuesday, February 14 @ 3:00 p.m EST.
about 3 days ago by abubnic
about 3 days ago by abubnic
@Trading4Cash I sold my PP at the close, same thing, made$$, I kind of regret selling my $affy one day early but go in early on that too!
about 8 days ago by professorkev
about 8 days ago by professorkev
@EXPstocktrader Are you on $AFFY too? Analyst have a $19 price target on it.
about 9 days ago by MaddStocks
about 9 days ago by MaddStocks
great run up in $AFFY this was the last squeeze as shorts took over for the time being. Locked in 10.45 reestablishing another entry
about 9 days ago by ACE52WeekHigh
about 9 days ago by ACE52WeekHigh
$AFFY Shares Given New $19.00 Price Target by Piper Jaffray Analysts. http://stks.co/2EAA
about 10 days ago by abubnic
about 10 days ago by abubnic
Affymax Promotes Cynthia Smith to Vice President, Market Access and Commercial Development
Feb 02, 4:00PM Business Wire
Feb 02, 4:00PM Business Wire
$AFFY beautiful. Approaching a beautiful rip towards $10. Vacuum buying in the mix!!!
about 10 days ago by ACE52WeekHigh
about 10 days ago by ACE52WeekHigh
Piper Jaffray Raises Target on Affymax (AFFY) to $19 Amid Optimistic Peginesatide Numbers
Feb 02, 11:40AM Street Insider
Feb 02, 11:40AM Street Insider
Baird Maintains an 'Outperform' on Affymax (AFFY); Even After Significant Model Revamp, It's Still A Buy
Dec 29, 7:07AM Street Insider
Dec 29, 7:07AM Street Insider
Takeda Pharmaceutical and Affymax (AFFX) Make Decision Not to Commercialize Peginesatide in Japan
Dec 15, 4:05PM Street Insider
Dec 15, 4:05PM Street Insider
Takeda and Affymax Provide Update on Peginesatide Commercialization Rights in Japan
Dec 15, 4:03PM Benzinga
Dec 15, 4:03PM Benzinga
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| AFFY | 10.47 | -0.06 | -0.57% | 372.21M |
| ALC | 16.34 | -0.16 | -0.97% | 374.68M |
| MCO | 38.44 | 0.07 | 0.18% | 8.53B |
| GE | 18.88 | -0.26 | -1.33% | 199.27B |
| GAIA | 3.64 | 0.15 | 4.30% | 84.88M |
| ANEN | 18.30 | -0.15 | -0.81% | 275.23M |
| PG | 63.88 | -0.16 | -0.25% | 175.75B |
| DD | 51.15 | -0.91 | -1.75% | 47.26B |
| AIG | 26.66 | -0.69 | -2.52% | 50.60B |
| ABVT | 69.42 | -0.61 | -0.87% | 1.79B |
